tbuckley/cabot-search huggingface dataset:
SAT0238 SHORT TERM PROGNOSIS OF A PROSPECTIVELY FOLLOWED COHORT OF UNSELECTED ADULT IGA VASCULITIS PATIENTS – A SINGLE RHEUMATOLOGY CENTRE EXPERIENCE
Authors: Jaka Ostrovrsnik, Ziga Rotar, Matija Tomsic, Alojzija Hocevar
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> The acute phase of adult IgA vasculitis (IgAV) is well characterized. Data of even short-term prognosis of adult IgAV is scarce, mostly retrospective and usually limited to patients with significant renal disease. <h3>Objectives</h3> Our aim was to examine the short-term prognosis in a cohort of unselected adult IgAV cases. <h3>Methods</h3> We analysed medical records of newly diagnosed, histologically proven cases of IgAV at our department of rheumatology between 1 January 2010 and 31 May 2018, that were followed until 30 November 2018. <h3>Results</h3> During the 101-month observational period we identified 245 IgAV cases. The clinical characteristics at presentation and the initial treatment are shown in Table 1. During the acute phase of the disease four patients died (3 due to active vasculitis, 1 due to generalized CMV infection and heart failure). During the follow-up period 23 patients died, all deaths were unrelated to IgAV. 28 patients were lost to follow-up. The clinical characteristics of the remaining 190 patients who were followed for a median 12.7 (IQR 6.9–24.5) months at follow-up are shown in Table 2. <h3>Conclusion</h3> Contrary to the experience in children, IgAV in adults does not seem to be a benign disease even in the short-term. Admittedly, it is impossible to conclude whether this is due to the nature of the adult IgAV or because adults have more comorbidities than children. <h3>Disclosure of Interests</h3> None declared
A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)
Authors: Jennifer A. Woyach, Amy S. Ruppert, Farrukh Awan, Jeffrey A. Jones, Sharon Waymer, Gerard Lozanski, Natarajan Muthusamy, John C. Byrd
Journal: Blood (2015)
AB0796 The Predictors of Fracture in Patients with Hyperparathyroidism: An Observational Study: Table 1
Authors: S. Ashraf, B. Khan, R. Sinha, M. Bukhari
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hyperparathyroidism and other endocrine disorders have been associated with a low bone mineral density. The FRAX ™ tool uses the femoral neck to predict fractures on a population basis and ignores the lumbar spine. <h3>Objectives</h3> We set out to determine the predictors of fragility fractures in a large cross sectional study of 508 patients diagnosed with Hyperparathyroidism. <h3>Methods</h3> Patients referred for bone mineral density (BMD) estimation in a scanner in the North West of England with a history of Hyperparathyroidism were identified from a dual X-ray absorptiometry (DEXA) database. Demographics and other risk factors were recorded as well as fragility fractures. Initially, Univariate logistic regression models were modelled predicting fractures in the data set and a multivariate model was subsequently fitted. Variables included age at scan, gender, body mass index (BMI), family history of fracture, alcohol intake, smoking, glucocorticoid exposure, rheumatoid arthritis, in addition to BMD in the lumbar spine and femoral neck. <h3>Results</h3> 508 patients were scanned in the referral period. Mean age at scan was 65.0 (SD 12.4). 411 (80.9%) of the patients were female and 97 were male. Results of the univariate analysis (adjusted for age and gender) are shown in table 1. Significant predictors are denoted with an asterisk. In the multivariate model, the only variable that predicted fractures in this cohort was Lumbar spine BMD OR 0.18 (95% CI 0.31,1.04) <h3>Conclusions</h3> In the univariate analysis, many risk factors are associated with fracture. However in the multivariate analysis conducted, the best predictor was Lumbar Spine BMD. This is not included in the FRAX ™ tool and would make estimating the fracture risk in this cohort difficult. Further modelling in other cohorts is needed to validate this finding. <h3>Disclosure of Interest</h3> None declared
The Effect of Short-Term Simvastatin On Markers of Vascular Dysfunction in Patients with Sickle Cell Disease (SCD).
Authors: Carolyn C. Hoppe, Kathryn R. Stewart, Annie Higa, Sandra Larkin, James K. Liao, Lori A. Styles, Elliott P. Vichinsky, Frans A. Kuypers
Journal: Blood (2009)
Characterization of Secondary Alterations in Mantle Cell Lymphomas Using Matrix-/Array CGH.
Authors: Doris Steinemann, Marcel Tauscher, Cornelia Rudolph, Makito Emura, M. Abe, M. Daibata, Yoshinobu Matsuo, Hans G. Drexler, Bernhard Radlwimmer, Hans A. Kestler, Peter Lichter, Brigitte Schlegelberger
Journal: Blood (2004)
THU0625 Healthcare Professionals' Perspectives on The Design and Implementation of An Early Integrated Care Intervention for Musculoskeletal Pain in The Irish Healthcare Setting: A Qualitative Study
Authors: N.M. Higgins, A. Cochrane, O. FitzGerald, P. Gallagher, J. Ashton, R. Breen, A. Brennan, O. Corcoran, D. Desmond
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Musculoskeletal disorders are amongst the leading causes of disability in the working age population. Growing evidence suggests early screening and targeted interventions during the acute phase can promote work retention and prevent disability. <h3>Objectives</h3> This study aims to develop and feasibility test an early, case manager-led intervention focusing on work as a clinical outcome. Here we report qualitative findings from focus groups and interviews conducted to consider issues of content, delivery and optimal timing, and to explore key priorities and potential challenges in service delivery. <h3>Methods</h3> Two focus groups and three individual interviews were conducted, involving 17 experts representing the multidisciplinary team. Thematic analysis was used to summarise the views and ideas expressed. <h3>Results</h3> Participants highlighted the importance of early access to diagnosis, relevant investigations and referral to specialists as necessary in reducing the risk of long term disability; noting the critical importance of GPs in facilitating early access. The need to provide reassurance and education about the patient9s condition was highlighted, as was the importance of screening for psychosocial risk factors. Patients most likely to benefit from the intervention were identified as those highly motivated to maintain their current work roles. Ready access to the MDT and the skill set of the case manager were noted as critical concerns, resource constraints pose considerable challenges. <h3>Conclusions</h3> Introduction of an early integrated care intervention that targets risk of work disability is warranted. Considerable “buy-in” is required from all stakeholders involved. The data will help to inform the planned feasibility study. <h3>Acknowledgement</h3> We would like to thank all of the individuals who participated in the interviews and focus groups. <h3>Disclosure of Interest</h3> None declared
Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.
Authors: Fei Fei, Yingzhe Yu, Anita Schmitt, Jinfei Chen, Baoan Chen, Markus Rojewski, Mark Ringhoffer, Stefanie von Harsdorf, Jochen Greiner, Marlies Goetz, Philippe Guillaume, Hartmut Dohner, Donald Bunjes, Michael Schmitt
Journal: Blood (2007)
Bone Involvement in Patients with Non-Neuronopathic Gaucher Disease Is Characterized by Increased Osteoclast Function Partially Due to High Circulating C-C Motif Ligand 3,
Authors: Veroniki Komninaka, Theodore Marinakis, Dimitrios Christoulas, Konstantina Repa, Dionysia Kolomodi, Maria Mitropoulou, Maria Gkotzamanidou, Athanasios Papatheodorou, Nikolaos Anagnostopoulos, Meletios Athanasios Dimopoulos, Evangelos Terpos
Journal: Blood (2011)
P1.47: ABOUND.sqm QoL by Response: Interim Analysis of Squamous NSCLC Pts Treated With nab-Paclitaxel/Carboplatin Induction Therapy
Authors: Corey Langer, Vera Hirsh, Katayoun I. Amiri, Amy Ko, Jeanna Knoble, Melissa Johnson, Robert Jotte, Michael Mccleod, Teng Jin Ong, Ray Page, David Spigel, Howard J. West, Nataliya Trunova
Journal: Journal of Thoracic Oncology (2016)
Efficient Erythropoiesis From Human Embryonic Stem Cells Through Dimerization of Intracellular MPL.
Authors: William Sang Kim, Gautam G. Dravid, Yuhua Zhu, Chintan Parekh, Qiming Deng, Roger P. Hollis, Timothy Lane, Donald B. Kohn, Gay M. Crooks
Journal: Blood (2012)
FRI0179 anti-TNF Therapy Is Associated with An Impaired Function of Nk Cells and A Defective Immunosurveillance against B-Cell Lymphomas
Authors: G. Nocturne, B. Ly, S. Boudaoud, R. Seror, L. Zitvogel, X. Mariette
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is associated with an increased risk of lymphoma linked to activity of the disease. Immunosuppressive drugs have been suspected to induce an additional risk. Since, NK cells have been recently shown to participate to anti–lymphoma immunosurveillance, we aimed to assess if anti-TNF might impact their anti-lymphoma activity. <h3>Methods</h3> NK cells have been assessed ex vivo in patients with RA treated with methotrexate (MTX) with (n=19) or without (n=20) anti-TNF. Phenotype has been studied by flow cytometry and function (degranulation and IFNg production) has been assessed after NKp30-cross linking. Then, we have studied the consequences of in vitro exposure of NK to anti-TNF, to TNF-R inhibitors or to controls during 6 days: phenotype has been studied and then cytotoxicity against 2 B non-Hodgkin lymphoma cell lines [Farage (EBV+) and SU-DHL4 (EBV-)] was assessed. Results are shown as median [interquartile range (IGR)]. The Mann Whitney test was used to compare independent samples. <h3>Results</h3> Firstly, in patients, we found that the proportion of activated NK cells, assessed by the expression of CD69, was significantly decreased in patients treated with anti-TNF + MTX compared to patients treated with MTX alone (8.9% [2.9–40.7] vs 48.4% [27.4–58.3], p=0.005). Moreover, we found that NK cells exhibited an impaired function in patients treated with anti-TNF compared to patients treated with MTX alone as assessed by the percentage of degranulation (20.9% [18.5–32.9] vs 31.3% [21.5–49.1], p=0.04) and the loss of capacity of IFN-γ secretion ((17.4% [8.9–25.9] vs to 29.7% [22.5–43.1], p=0.007). Secondly, we have confirmed that in vitro exposure to anti-TNF negatively impact NK cells activation and function leading to an impaired anti-lymphoma activity (figure 1A). In all these experiments, no difference was observed between etanercept and monoclonal anti-TNF. Last, we have demonstrated that negative impact of anti-TNF on NK cells may be the consequence of inhibition of TNF-R1 signaling (figure 1B). <h3>Conclusions</h3> Even if meta-analysis of randomized controlled trials and of registries have not demonstrated to date an increased risk of lymphoma with anti-TNF, cautious must be pursued concerning this possible side effect in patients with long-term exposure. Moreover, negative impact of anti-TNF on NK cells may participate to infectious adverse events. <h3>Disclosure of Interest</h3> None declared
THU0408 Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from The International Comospa Study
Authors: M. Couderc, M. Soubrier, B. Pereira, A. Molto, M. Dougados
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Renal impairement in spondyloarthritis (SpA), although uncommon, may include secondary renal amyloidosis (AA type), non-steroidal anti-inflammatory drug (NSAID) nephropathy, and glomerulonephritis. Data on the prevalence of renal impairement in SpA are relatively rare and usually come from small or retrospective studies. <h3>Objectives</h3> To assess the prevalence and associations of renal dysfunction in patients with SpA. <h3>Methods</h3> COMOSPA was an international (22 participating countries from four continents) multicentric study on comorbidities in SpA. Renal function was assessed from the estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation. SpA characteristics, risk factors for renal impairment were collected. NSAID use was assessed by the currently (last 3 months) intake. Logistic regression models were constructed from variables which were significantly associated with an eGFR of &lt;60ml/min/1.73m<sup>2</sup> or clinically relevant. <h3>Results</h3> Of the 3984 recruited patients, after excluding of outliers and patients for whom eGFR was not available, 2098 (52.6%) were analysed (male gender: 63.5%; age: 45.3 years; disease duration: 8.6 years; HLAB27+: 53.7%; BASDAI: 3.6/10). A total of 153 patients (5.2%, mean age 53.6 years) had an eGFR &lt;60 ml/min/m<sup>2</sup>. In univariate analysis, renal impairment was associated with age (p&lt;0.001), HLAB27 positivity (p&lt;0.001), several cardiovascular risk factors (history of hypertension [p&lt;0.001], systolic blood pressure [p=0.03], diabetes [p=0.005] and the Framingham Risk score [p&lt;0.001]), disease activity scores (BASDAI [p=0.001], ASDAS-CRP [p&lt;0.001]), functionnal parameters (BASFI [p&lt;0.001], HAQ [p&lt;0.001]), inflammatory biomarkers (ESR and CRP, both p&lt;0.001), but not with disease duration, disease sevrity (bamboo spine, hip replacement) or NSAID current intake. <h3>Conclusions</h3> Renal impairment is not rare in SpA and is associated with age, disease severity and inflammation but not with cardiovascular risk factors or NSAID currently use. <h3>Disclosure of Interest</h3> None declared
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years
Authors: Maria Gavriatopoulou, Ramón García-Sanz, Efstathios Kastritis, Pierre Morel, Marie-Christine Kyrtsonis, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, Pieter Sonneveld, Meletios A. Dimopoulos
Journal: Blood (2016)
Abstract 3152: Hyperdynamic Circulatory State And Volume Overload Without Left Ventricular Intrinsic Myocardial Dysfunction Is Detected In Normotensive Non Diabetic Patients With Morbid Obesity
Authors: Michaela Kozakova, Emona Malshi, Carmela Morizzo, Elza Muscelli, Stefania Camastra, Monica Nannipieri, Eleuterio Ferrannini, Carlo Palombo
Journal: Circulation (2007)

Background: increasing reports suggest that morbid obesity (BMI ≥ 40 kg/m2) is associated with an early impairment of intrinsic myocardial function, possibly contributing to an increased susceptibility to heart failure. However, the relative role of obesity and associated comorbidities such as HBP and diabetes in LV dysfunction is still unclear. Aim of the study: to investigate subclinical cardiovascular involvement in patients with isolated morbid obesity as compared to age-matched lean subjects. Methods: 38 lean healthy volunteers (BMI ≤ 25 kg/m2, 21 females, mean age 39 ± 11, BP 118 ± 9/69 ± 8 mmHg) and 29 non diabetic normotensive patients with morbid obesity (24 females, mean age 34 ± 10, BP 123 ± 10/78 ± 9 mmHg) were studied. LV geometry, pump function, midwall circumferential shortening, diastolic filling, myocardial longitudinal systolic and diastolic velocities, were evaluated by 2-D and M-mode echo, transmitral Doppler and Tissue Doppler Imaging of mitral annulus and interventricular septum and lateral wall (Aloka SSD-5500). Indices of aortic stiffness and arterial wave reflection were obtained by carotid-femoral pulse wave velocity (PWV) and carotid augmentation index (AIx). Ratio of stroke volume to pulse pressure (SV/PP) was used as an index of total arterial compliance Results: Compared to lean subjects, obese patients had significantly (p &lt; at least 0.05) higher HR (75 ± 10 vs 62 ± 9 bpm), LV diastolic diameter (5.5 ± 0.7 vs 5.0 ± 0.5 cm), LV mean wall thickness (0.85 ± 0.11 vs 0.73 ± 0.13), LVMI (51 ± 15 vs 34 ± 9 g/m2.7), cardiac output (6.9 ± 2.5 vs 4.9 ± 1.1 L), LV stroke work (160 ± 50 vs 135 ± 34 g-ml/beat), mitral A velocity (0.63 ± 0.14 vs 0.52 ± 0.12 m/s), E/Ea ratio (a Doppler index related to capillary pulmonary pressure: 6.6 ± 4.4 vs 4.5 ± 1.1) and SV/PP (2.0 ± 0.6 vs 1.6 ± 0.4 ml/mmHg). Total peripheral resistance was significantly lower (1199 ± 419 vs 1452 ± 360 dyn*s/cm5). No differences between groups were found for LV midwall systolic shortening, longitudinal myocardial velocities, PWV and AIx. Conclusion: young to middle age patients with morbid obesity still free of comorbidities show an hyperdynamic circulatory state associated to volume overload, without detectable subclinical abnormalities of intrinsic myocardial function and arterial function.
Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)
Authors: Andrew Davies, Francesco Merli, Biljana Mihaljevik, Noppadol Siritanaratkul, Philippe Solal-Céligny, Axel Boehnke, Claude Berge, Christine McIntyre, Martin Barrett, David Macdonald
Journal: Blood (2012)
NK Cell Activity Influences Long Term Outcome of Pediatric Leucemias After T Cell Depleted Stem Cell Transplantation,
Authors: Peter Lang, Matthias Pfeiffer, Heiko-Manuel Teltschik, Paul G. Schlegel, Tobias F. Feuchtinger, Thomas Klingebiel, James F. Beck, Rupert Handgretinger
Journal: Blood (2011)
Influence of G-CSF Mobilization and Liquid Storage Time on Post-Thaw Recovery of Lymphocyte Subpopulations and CD34+ Cells in Cryopreserved Apheresis Products
Authors: Christina Berens, Annkristin Heine, Jens Mueller, Johannes Oldenburg, Dominik Wolf, Bernd Poetzsch, Heiko Ruehl
Journal: Blood (2015)
Microenvironment Shields Myeloma From Adoptive Immunotherapy by Cell Adhesion Mediated Immune Resistance (CAM-IR),
Authors: Sanne J de Haart, Monique C. Minnema, Tineke Aarts-Riemens, Niels Bovenschen, Henk M. Lokhorst, Tuna Mutis
Journal: Blood (2011)
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Authors: Steven E. Nissen, Neville D. Yeomans, Daniel H. Solomon, Thomas F. Lüscher, Peter Libby, M. Elaine Husni, David Y. Graham, Jeffrey S. Borer, Lisa M. Wisniewski, Katherine E. Wolski, Qiuqing Wang, Venu Menon, Frank Ruschitzka, Michael Gaffney, Bruce Beckerman, Manuela F. Berger, Weihang Bao, A. Michael Lincoff
Journal: New England Journal of Medicine (2016)

The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal antiinflammatory drugs (NSAIDs), remains uncertain.
OP0183 Hypocomplementemia Associates with Thrombosis in SLE Patients with Antiphospholipid Antibodies: Table 1.
Authors: L. Durcan, W. Fu, M. Petri
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Low complement is common in systemic lupus erythematosus (SLE) and is considered in classification criteria and disease activity indices. Recent evidence supports the hypothesis that the activation of complement is also important in the antiphospholipid syndrome (APS), coating platelets and contributing to thrombus formation. The successful treatment of catastrophic APS with the terminal complement inhibitor, eculizumab, has been reported, supporting this hypothesis. <h3>Objectives</h3> This work was undertaken to evaluate the relationship between hypocomplementemia and thrombotic outcomes in SLE patients with antiphospholipid antibodies (APL). <h3>Methods</h3> As part of a longitudinal lupus cohort, the presence of antiphospholipid antibodies (lupus anticoagulant and anticardiolipin) and thrombotic events, both venous and arterial, were updated quarterly. Statistical analysis included only patients who were found on longitudinal follow up to have one or more APL, i.e. antibodies to cardiolipin, or the presence of the lupus anticoagulant (LAC). Patients were then categorized by thrombotic event, the presence of hypocomplementemia (low C3, low C4 and both low C3 and C4) and type of APL. Those with low complement were compared to those without and the odds ratio for each thrombotic outcome calculated. <h3>Results</h3> 2399 patients were included, 1140 (47.5%) had antibodies to cardiolipin and 624 (26.0%) a positive LAC. The relationship between the antiphospholipid antibodies, thrombotic outcomes and low C3, low C4 or both in combination is outlined in Table 1. <h3>Conclusions</h3> In patients with anticardiolipin antibodies, the presence of hypocomplementemia (both low C3 + C4) associates strongly with DVT and stroke. Hypocomplementemia in the setting of the LAC was also associated with stroke whilst low C4 alone associated with digital gangrene. These findings are supportive of the robust mechanistic data involving the complement system in APS. They also raise the question as to whether hypocomplementemia should be considered a further risk factor for thrombosis in SLE patients with positive antiphospholipid antibodies in whom to date many traditional risk factors have been implicated. <h3>Disclosure of Interest</h3> None declared
The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses
Authors: Rachael F. Grace, Ellis J. Neufeld, A. Kim Ritchey, Manjusha Kumar, Michael R. Jeng, Victor Blanchette, Robert Klaassen, George R. Buchanan, Margaret A. Heisel Kurth, Diane J. Nugent, Alexis A. Thompson, Courtney Thornburg, Michele P. Lambert, Michelle D. Neier, Michael Recht, Kimo Stine, Leslie A. Kalish, Carolyn M. Bennett
Journal: Blood (2010)
Salvage Therapy of Progressive and Recurrent Hodgkin’s Disease: Results from a Multicenter Study of the Pediatric DAL/GPOH HD-Study Group.
Authors: Guenther Schellong, Wolfgang Doerffel, Alexander Claviez, Dieter Koerholz, Georg Mann, Hans G. Scheel-Walter, Jos P.M. Boekkerink, Marianne Riepenhausen, Heike Lueders, Richard Poetter, Ursula Ruehl
Journal: Blood (2004)
Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients.
Authors: Fabio P.S. Santos, Ellen Schlette, Hagop Kantarjian, Rachel Sargent, Guillermo Garcia-Manero, Srdan Verstovsek, Tapan Kadia, Elias Jabbour, Sherry Pierce, Gautam Borthakur
Journal: Blood (2009)
Racial Differences in Thrombotic Risk Factors Associated with Adverse Pregnancy Outcome Among Women Obtaining Care in US Thrombosis and Hemostasis Centers.
Authors: Claire S. Philipp, Ambarina Faiz, Sheetal Shrimanker, Michele G Beckman, Paula L. Bockenstedt, Andra H James, Marilyn J. Manco-Johnson
Journal: Blood (2009)